Modern Healthspan: Dr David Sinclair’s Reprogramming Tech in Human Trials
Peer-Reviewed Research
Key Takeaways
- ER-100 is the first FDA-cleared epigenetic reprogramming therapy to enter human trials, targeting age-related eye diseases.
- The therapy resets epigenetic markers without full dedifferentiation (using OSK factors, excluding c-Myc) to restore youthful cell function.
- Phase 1 trial focuses on safety in glaucoma and NAION patients via single intravitreal injection + 8 weeks of oral doxycycline activation.
- Preclinical data showed vision restoration in mice and primates, including post-injury recovery and epigenetic pattern resetting.
Notable Quotes
“Partial epigenetic reprogramming aims at something further upstream… It targets the epigenome, the layer of biochemical markers that sit on top of your DNA.”
Bottom Line
Track trial NCT07290244 for initial safety data by late 2026. If successful, this could pioneer a new class of epigenetic therapies for aging-related diseases.
Explore More
- Modern Healthspan’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network